文献速递临床免疫分子诊断

中国汉族系统性硬化症患者自身抗体谱的 commercial 免疫检测评估

Evaluation of a commercial immunoassay for autoantibodies in Chinese Han systemic sclerosis population.
PubMed 文献 · Clin Chim Acta · 2019-01-24

本研究采用 Euroline 系统性硬化症谱试剂盒,检测 320 例中国汉族 SSc 患者、100 例非 SSc 结缔组织病患者和 30 例健康对照的血清自身抗体。结果显示 SSc 患者抗 RP11、CENPB、CENPA 和 Scl-70 阳性率升高,抗 Ro-52 阳性率降低;抗 Ro-52 和抗 Scl-70 对 ILD 有预测价值,抗 Ro-52 对 PAH 有预测价值。

要点

  • 抗 RP11、CENPB、CENPA 和 Scl-70 有助于中国汉族人群 SSc 诊断。
  • SSc 合并 ILD 者抗 Ro-52 和抗 Scl-70 阳性率升高,抗 CENPB 和 CENPA 降低。
  • 抗 Ro-52 对 SSc 相关 PAH 有潜在预测价值。

核心结论

  • 商业免疫印迹法对中国汉族 SSc 具有较好诊断效用。
  • 抗 Ro-52、RP11、CENPB、CENPA 和 Scl-70 有助于中国汉族人群 SSc 诊断。
  • 抗 Ro-52、CENPB、CENPA 和 Scl-70 对 SSc 患者 ILD 诊断有潜在价值,抗 Ro-52 和 Scl-70 可能用于诊断 PAH。

研究设计与样本

  • 采用 Euroline 系统性硬化症谱试剂盒检测血清自身抗体。
  • 纳入健康对照 30 例、SSc 患者 320 例、非 SSc 结缔组织病患者 100 例。

主要发现

  • 与非 SSc CTD 相比,SSc 患者抗 RP11(P=0.032)、抗 CENPB(P<0.001)、抗 CENPA(P=0.001)和抗 Scl-70(P<0.001)阳性率升高,抗 Ro-52(P=0.004)降低。
  • 与健康对照相比,SSc 患者抗 Ro-52(P=0.003)、抗 CENPB(P=0.034)、抗 CENPA(P=0.034)和抗 Scl-70(P<0.001)阳性率升高。
  • SSc 合并 ILD 者抗 Ro-52(P=0.046)和抗 Scl-70(P=0.035)阳性率升高,抗 CENPB(P<0.001)和抗 CENPA(P<0.001)降低。
  • SSc 合并 PAH 者抗 Ro-52(P=0.013)阳性率升高,抗 Scl-70(P=0.001)降低。

关键数值与推荐

  • 抗 Ro-52 和抗 Scl-70 对 SSc 患者 ILD 的预测价值升高。
  • 抗 Ro-52 对 SSc 患者 PAH 的预测价值升高。

临床怎么用

  • 可采用商业线性免疫印迹法检测中国汉族 SSc 患者自身抗体谱。
  • 抗 Ro-52、RP11、CENPB、CENPA 和 Scl-70 可用于 SSc 诊断。
  • 抗 Ro-52、CENPB、CENPA 和 Scl-70 可辅助评估 SSc 患者 ILD 风险。
  • 抗 Ro-52 和 Scl-70 可辅助评估 SSc 患者 PAH 风险。

局限性

  • 仅纳入中国汉族人群,结果外推需谨慎。
  • 健康对照样本量较小(n=30)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The autoantibody profile, which varies between races, has rarely been reported in Chinese Han systemic sclerosis (SSc) patients. The present study aims to investigate the autoantibody profile of Chinese Han SSc patients using a commercial line immunoassay. METHODS: The prevalence of autoantibodies to Ro-52, PDGFR, Ku, PM75, PM100, Th/To, NOR90, Fib, RP155, RP11, CENP-B, CENP-A and Scl-70 were analyzed in serum samples obtained from healthy controls (n = 30), SSc patients (n = 320) and non-SSc connective-tissue disease patients (n = 100) using an Euroline Systemic Sclerosis Profile kit. RESULTS: SSc patients had increased prevalence of anti-RP11 (P = 0.032), anti-CENPB (P < 0.001), anti-CENPA (P = 0.001) and anti-Scl-70 (P < 0.001), but had decreased prevalence of anti-Ro-52 (P = 0.004), when compared to non-SSc CTDs. Furthermore, SSc patients had increased prevalence of anti-Ro-52 (P = 0.003), anti-CENPB (P = 0.034), anti-CENPA (P = 0.034) and anti-Scl-70 (P < 0.001), when compared to HCs. In addition, SSc patients with interstitial lung disease (ILD) had increased prevalence of anti-Ro-52 (P = 0.046) and anti-Scl-70 (P = 0.035), but had decreased prevalence of anti-CENPB (P < 0.001) and anti-CENPA (P < 0.001). Moreover, SSc patients with pulmonary arterial hypertension (PAH) had increased prevalence of anti-Ro-52 (P = 0.013) and decreased prevalence of anti-Scl-70 (P = 0.001). Anti-Ro-52 and anti-Scl-70 had increased values for predicting ILD in SSc patients, while anti-Ro-52 had increased values for predicting PAH in SSc patients. CONCLUSION: A commercial line immunoassay was used to evaluate the diagnostic value of autoantibodies in Chinese Han SSc patients. The results clearly indicate that the immunoblot assay has good diagnostic utility for SSc. Anti-Ro-52, anti-RP11, anti-CENPB, anti-CENPA and anti-Scl-70 are useful for diagnosing SSc in the Chinese Han population. Anti-Ro-52, anti-CENPB, anti-CENPA and anti-Scl-70 have a potential value for diagnosing ILD in SSc patients. Furthermore, anti-Ro-52 and anti-Scl-70 may be used to diagnose PAH in SSc patients.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Liu C, Hou Y, Yang Y, et al. Evaluation of a commercial immunoassay for autoantibodies in Chinese Han systemic sclerosis population. Clin Chim Acta. 2019. PMID: 30685360. doi:10.1016/j.cca.2019.01.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。